<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037385</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-667-1101</org_study_id>
    <secondary_id>2016-004390-41</secondary_id>
    <nct_id>NCT03037385</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors</brief_title>
  <acronym>ARROW</acronym>
  <official_title>A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
      tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic
      activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid
      cancer, RET-altered NSCLC and other RET-altered solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase
      2). Both parts will enroll patients with advanced non-resectable NSCLC, advanced
      non-resectable thyroid cancer and other advanced solid tumors that have progressed following
      standard systemic therapy, have not adequately responded to standard systemic therapy, or the
      patients must be intolerant to or the Investigator has determined that treatment with
      standard therapy is not appropriate, or there must be no accepted standard therapy for their
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1 (Complete):
Advanced MTC, NSCLC or other solid tumor
30-600mg (PO QD or BID)
Phase 2 (400mg QD):
Group 1: RET fusion NSCLC previously treated with a platinum chemotherapy
Group 2: RET fusion NSCLC not previously treated for metastatic disease
Group 3: MTC previously treated with cabozantinib and/or vandetanib
Group 4: MTC not previously treated with cabozantinib or vandetanib
Group 5: Other solid tumors with a RET fusion previously treated with SOC
Group 6: Any solid tumor with a RET alteration (fusion or mutation) previously treated with a selective RET Inhibitor
Group 7: Other solid tumors with a RET mutation previously treated with SOC</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Phase 1) Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of BLU-667</measure>
    <time_frame>Cycle 1 (28 days) of treatment for MTD and at the end of every cycle (28 days) for RP2D for approximately 12 months or earlier if patient terminates from the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 1) Number of patients with adverse events and serious adverse events</measure>
    <time_frame>Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study, and 30 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 2) Overall response rate</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
    <description>As assessed by RECIST v1.1 or RANO, as appropriate per tumor type</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 2) Number of patients with adverse events and serious adverse events</measure>
    <time_frame>Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study, and 30 days after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Phase 1) Overall response rate</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
    <description>As assessed by RECIST v1.1 or RANO, as appropriate per tumor type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 1) RET gene status and correlation between RET gene status and ORR, CBR, DOR, DCR, PFS and other antineoplastic measures</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 2 ) Clinical Benefit Rate (CBR)</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 2 ) Duration of Response (DOR)</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 2 ) Disease Control Rate (DCR)</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 2 ) Progression Free Survival (PFS)</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 2 ) Overall Survival (OS)</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 2) RET gene status and correlation between RET gene status and ORR, CBR, DOR, DCR and other antineoplastic measures</measure>
    <time_frame>Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (up to 2 years) in patients without progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phases 1 and 2) Pharmacokinetic parameters including maximum plasma drug concentration (Cmax)</measure>
    <time_frame>Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phases 1 and 2) Pharmacokinetic parameters including area under the plasma concentration versus time curve from time 0 to 24 hours postdose (AUC0-24)</measure>
    <time_frame>Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phases 1 and 2) Pharmacokinetic parameters including terminal elimination half-life (t1/2)</measure>
    <time_frame>Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 2) Electrocardiogram (ECG) Assessment using QT analysis</measure>
    <time_frame>Effects of BLU-667 on ECG parameters on Cycle 1 Day 1 and Cycle 1 Day 15</time_frame>
    <description>Will be measured from lead II and will be corrected for heart rate (QTc)n using Fridericia's correction factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phases 1 and 2) Pharmacodynamic parameters including changes in blood calcitonin</measure>
    <time_frame>Approximately every 2 weeks in Cycle 1 and monthly through Cycle 3 and every other month through Cycle 13</time_frame>
    <description>MTC patients only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phases 1 and 2) Pharmacodynamic parameters including tumor marker, carcinoembryonic antigen (CEA)</measure>
    <time_frame>Approximately every 2 weeks in Cycle 1 and monthly through Cycle 3 and every other month through Cycle 13</time_frame>
    <description>MTC patients only</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">527</enrollment>
  <condition>RET-altered Non Small Cell Lung Cancer</condition>
  <condition>Medullary Thyroid Cancer</condition>
  <condition>RET-altered Papillary Thyroid Cancer</condition>
  <condition>RET-altered Colon Cancer</condition>
  <condition>RET-altered Solid Tumors</condition>
  <condition>Lung Neoplasm</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Thyroid Diseases</condition>
  <condition>Thyroid Neoplasm</condition>
  <condition>Thyroid Cancer, Papillary</condition>
  <condition>Carcinoma, Neuroendocrine</condition>
  <condition>Respiratory Tract Neoplasms</condition>
  <condition>Thoracic Neoplasms</condition>
  <condition>Neoplasms by Site</condition>
  <condition>Neoplasms</condition>
  <condition>Lung Diseases</condition>
  <condition>Respiratory Tract Disease</condition>
  <condition>Carcinoma, Bronchogenic</condition>
  <condition>Bronchial Neoplasms</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Endocrine Gland Neoplasm</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Adenocarcinoma, Papillary</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Carcinoma</condition>
  <condition>Neoplasms, Glandular and Epithelial</condition>
  <condition>Neoplasms by Histologic Type</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Neuroectodermal Tumors</condition>
  <condition>Neoplasms, Germ Cell and Embryonal</condition>
  <condition>Neoplasms, Nerve Tissue</condition>
  <condition>Colonic Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Intestinal Neoplasms</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Digestive System Neoplasm</condition>
  <condition>Digestive System Disease</condition>
  <condition>Gastrointestinal Disease</condition>
  <condition>Colonic Diseases</condition>
  <condition>Intestinal Disease</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of pralsetinib (BLU-667) for oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose of pralsetinib (BLU-667) as determined during Dose Escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pralsetinib (BLU-667)</intervention_name>
    <description>pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants</description>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
    <other_name>BLU-667</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis during dose escalation (Phase 1) - Pathologically documented, definitively
             diagnosed non-resectable advanced solid tumor.

               -  All patients treated at doses &gt; 120 mg per day must have medullary thyroid cancer
                  (MTC), or a RET-altered solid tumor per local assessment of tumor tissue and/or
                  blood.

          -  Diagnosis during dose expansion (Phase 2) - All patients (with the exception of Groups
             3 and 4) must have an oncogenic RET-rearrangement/fusion or mutation (excluding
             synonymous, frameshift, and nonsense mutations) solid tumor, as determined by local or
             central testing of tumor or circulating tumor nucleic acid in blood; as detailed
             below.

               -  Group 1 - patients must have pathologically documented, definitively diagnosed
                  locally advanced or metastatic NSCLC with a RET fusion previously treated with a
                  platinum-based chemotherapy.

               -  Group 2 - patients must have pathologically documented, definitively diagnosed
                  locally advanced or metastatic NSCLC with a RET fusion not previously treated
                  with a platinum-based chemotherapy, including those who have not had any systemic
                  therapy. Prior platinum chemotherapy in the neoadjuvant and adjuvant setting is
                  permitted if the last dose of platinum was 4 months or more before the first dose
                  of study drug.

               -  Group 3 - patients must have pathologically documented, definitively diagnosed
                  advanced MTC that has progressed within 14 months prior to the Screening Visit
                  and was previously treated with cabozantinib and/or vandetanib.

               -  Group 4 - patient must have pathologically documented, definitively diagnosed
                  advanced MTC that has progressed within 14 months prior to the Screening Visit
                  and was not previously treat with cabozantinib and/or vandetanib.

               -  Group 5 -patients must have a pathologically documented, definitively diagnosed
                  advanced solid tumor with an oncogenic RET fusion previously treated with SOC
                  appropriate for the tumor type and not eligible for any of the other groups.

               -  Group 6 - patients must have a pathologically documented, definitively diagnosed
                  advanced solid tumor with an oncogenic RET fusion or mutation that was previously
                  treated with a selective TKI that inhibits RET

               -  Group 7 - patients must have a pathologically documented, definitively diagnosed
                  advanced solid tumor with an oncogenic RET mutation previously treated with SOC
                  appropriate for the tumor type and not eligible for any of the other groups

          -  Patients must have non-resectable disease. Phase 1 only patients must have progressed
             following standard therapy or have not adequately responded to standard therapy, or
             the patient must be intolerant to, or the Investigator has determined that treatment
             with standard therapy is not appropriate, or there must be no accepted standard
             therapy for their disease.

          -  Patient has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.

        Key Exclusion Criteria:

          -  Patient's cancer has a known primary driver alteration other than RET. For example,
             NSCLC with a targetable mutation in EGFR, ALK, ROS1 or BRAF; colorectal with an
             oncogenic KRAS, NRAS, or BRAF mutation.

          -  Patient has any of the following within 14 days prior to the first dose of study drug:

               1. Platelet count &lt; 75 × 10^9/L.

               2. Absolute neutrophil count &lt;1.0 × 10^9/L.

               3. Hemoglobin &lt; 9.0 g/dL (red blood cell transfusion and erythropoietin may be used
                  to reach at least 9.0 g/dL, but must have been administered at least 2 weeks
                  prior to the first dose of study drug.

               4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 × the
                  upper limit of normal (ULN) if no hepatic metastases are present; &gt;5 × ULN if
                  hepatic metastases are present.

               5. Total bilirubin &gt; 1.5 × ULN; &gt; 3 × ULN with direct bilirubin &gt; 1.5 × ULN in
                  presence of Gilbert's disease.

               6. Estimated (Cockcroft-Gault formula) or measured creatinine clearance &lt;40 mL/min.

               7. Total serum phosphorus &gt;5.5 mg/dL

          -  QT interval corrected using Fridericia's formula (QTcF) &gt;470 msec or history of
             prolonged QT syndrome or Torsades de pointes, or familial history of prolonged QT
             syndrome.

          -  Clinically significant, uncontrolled, cardiovascular disease.

          -  Central nervous system (CNS) metastases or a primary CNS tumor that is associated with
             progressive neurological symptoms.

          -  Clinically symptomatic interstitial lung disease or interstitial pneumonitis including
             radiation pneumonitis

          -  Patients in Groups 1-5 and 7 (Phase 2) previously treated with a selective RET
             inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Blueprint Medicines</last_name>
    <phone>617-714-6707</phone>
    <email>studydirector@blueprintmedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, PA - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044-3257</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208-3412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jack D. Weiler Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461-2301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-1862</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705-1165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705-1165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington, Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Gongshu District</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang University - Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Zhejiang</city>
        <state>Hangzhou</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Hexi District</state>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial Academy of Medical Sciences - Gansu Provincial Cancer Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Qilihe District</state>
        <zip>730050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Shapingba District</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Shapingbaqu</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The affiliated Cancer Hospital, School of Medicine, UESTC</name>
      <address>
        <city>Chengdu</city>
        <state>Wuhou District</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University - Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Gannan Medical University</name>
      <address>
        <city>Ganzhou</city>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Gannan Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Hanzhou</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <zip>230031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gansu provincial cancer hospital</name>
      <address>
        <city>Lanzhou</city>
        <zip>730050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Institute</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Hurier Servide d'Endocrinologie et Diabétologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>6100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Insitut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Emil von Behring</name>
      <address>
        <city>Berlin</city>
        <zip>14165</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Munchen</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pius-Hospital Oldenberg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Rome</city>
        <zip>144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>6351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169160</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Duran I Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre Servicio de Oncologia Medica</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHS Grampian - Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital St. Thomas NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ret-arrowtrial.com/</url>
    <description>More information about the study</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RET Lung</keyword>
  <keyword>RET Thyroid</keyword>
  <keyword>RET fusion</keyword>
  <keyword>RET alteration</keyword>
  <keyword>RET mutation</keyword>
  <keyword>RET positive</keyword>
  <keyword>RET inhibitor</keyword>
  <keyword>RET altered</keyword>
  <keyword>RET rearrangement</keyword>
  <keyword>RET NSCLC</keyword>
  <keyword>RET medullary thyroid cancer</keyword>
  <keyword>RET-rearranged NSCLC</keyword>
  <keyword>RET-rearranged thyroid</keyword>
  <keyword>M918T</keyword>
  <keyword>TRIM33-RET</keyword>
  <keyword>RET fusion lung cancer</keyword>
  <keyword>RET fusion thyroid cancer</keyword>
  <keyword>lung cancer mutation</keyword>
  <keyword>BLU 667</keyword>
  <keyword>RET tyrosine kinase</keyword>
  <keyword>RET gene mutation</keyword>
  <keyword>RET kinase</keyword>
  <keyword>RET MTC</keyword>
  <keyword>advanced lung cancer</keyword>
  <keyword>advanced non small cell lung cancer</keyword>
  <keyword>metastatic lung cancer</keyword>
  <keyword>KIF5B-RET</keyword>
  <keyword>CCDC6-RET</keyword>
  <keyword>NCOA4-RET</keyword>
  <keyword>advance solid tumor</keyword>
  <keyword>V804L</keyword>
  <keyword>V804M</keyword>
  <keyword>thyroid cancer RET inhibitor</keyword>
  <keyword>lung cancer RET inhibitor</keyword>
  <keyword>RET PTC</keyword>
  <keyword>rearranged during transfection</keyword>
  <keyword>RET-PTC1</keyword>
  <keyword>RET-PTC</keyword>
  <keyword>RET-PTC3</keyword>
  <keyword>RET-PTC4</keyword>
  <keyword>PRKAR1A-RET</keyword>
  <keyword>RET-PTC2</keyword>
  <keyword>GOLGA5-RET</keyword>
  <keyword>RET-PTC5</keyword>
  <keyword>ERC1-RET</keyword>
  <keyword>KTN1-RET</keyword>
  <keyword>RET-PTC8</keyword>
  <keyword>HOOK3-RET</keyword>
  <keyword>PCM1-RET</keyword>
  <keyword>TRIM24-RET</keyword>
  <keyword>RET-PTC6</keyword>
  <keyword>TRIM27-RET</keyword>
  <keyword>RET-PTC7</keyword>
  <keyword>AKAP13-RET</keyword>
  <keyword>FKBP15-RET</keyword>
  <keyword>SPECC1L-RET</keyword>
  <keyword>TBL1XR1-RET</keyword>
  <keyword>BCR-RET</keyword>
  <keyword>FGRF1OP-RET</keyword>
  <keyword>RFG8-RET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Neoplasms by Site</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Thoracic Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Respiratory Tract Neoplasms</mesh_term>
    <mesh_term>Bronchial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Neoplasms, Nerve Tissue</mesh_term>
    <mesh_term>Adenocarcinoma, Papillary</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Colonic Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

